CYTK
CytokineticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful regulatory feedback and positive clinical readouts lead to accelerated development/partner milestones; market awards a premium for near-term commercial optionality and partnership upside.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.0.
What can break
Unfavorable FDA guidance, failed readouts, or a tightened cash runway force dilution or partnership concessions; shares reprice materially lower.
Momentum
85
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.37 · Bull $4.28 · Bear $2.14
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $91.17
Why
Momentum85 · Δ7d -3.0
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
85
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.0
Δ21d
+14.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 84.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$9.17B
Beta
0.54
Shares Out
122.26M
P/E (TTM) · Derived
-11.5
P/S (TTM)
85.88
P/FCF (TTM) · Derived
-19.68
Rev YoY
+318.1%
EPS YoY
-87.1%
Gross Margin
-
Op Margin
-796.0%
Net Debt
-$418.9M
Current Ratio
6.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology